{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-107409","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.545882+00:00","generated_at":"2026-06-23T04:15:10.596236+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"United Therapeutics enrolls first patient in Phase 3 TETON 2 study of Tyvaso for IPF","bullets":["First patient enrolled in Phase 3 TETON 2 study of Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).","Study targets 396 adult IPF patients at sites outside the US and Canada; 52-week treatment evaluating forced vital capacity (FVC).","Tyvaso is already FDA-approved for PH-ILD but not for IPF without documented pulmonary hypertension.","TETON program builds on positive FVC impact observed in the INCREASE study of inhaled treprostinil in IPF patients with PH."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-107409","json":"https://secwatch.observer/filing/0001104659-22-107409.json","markdown":"https://secwatch.observer/filing/0001104659-22-107409.md","text":"https://secwatch.observer/filing/0001104659-22-107409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922107409/0001104659-22-107409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922107409/tm2227915d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:15:10.596236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}